When was Sonnet BioTherapeutics founded?

Sonnet BioTherapeutics was founded in 2011 and raised its 1st funding round 8 years after it was founded.

Where is Sonnet BioTherapeutics located?

Sonnet BioTherapeutics is headquartered in Princeton, United States.

How many employees does Sonnet BioTherapeutics have?

As of Mar 31, 2026, the latest employee count at Sonnet BioTherapeutics is 12.

Is Sonnet BioTherapeutics a funded company?

Sonnet BioTherapeutics is a funded company, having raised a total of $750K across 4 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on May 14, 2019.

When was the latest funding round of Sonnet BioTherapeutics?

Sonnet BioTherapeutics' latest funding was a $***** Post IPO round on Dec 10, 2024, with participation from 0 investor.

What is the annual revenue of Sonnet BioTherapeutics?

Annual revenue of Sonnet BioTherapeutics is $1M as on Sep 30, 2025.

Where does Sonnet BioTherapeutics rank among its competitors?

Sonnet BioTherapeutics ranks 1031st amongst 3189 active competitors, of which 1086 are funded.

Who are the top competitors of Sonnet BioTherapeutics?

Sonnet BioTherapeutics' top competitors include Jazz Pharmaceuticals, Moderna and Advanced Accelerator Applications. Among them, Sonnet BioTherapeutics secured the most recent funding round in December, 2024.

Sonnet BioTherapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of immunotherapies for the treatment of cancer. The company has proprietary FHAB™ (Fully Human Albumin Binding) technology that empowers the development of innovative targeted biologic drugs with enhanced single- or bi-specific mechanisms. The company's lead compound is SON-1010 for solid tumors.

Website: sonnetbio.com
Email ID: *****@sonnetbio.com
Phone Number: +1 **********

Key Metrics

Founded Year

2011

Location

Princeton, United States

Stage

Public

Total Funding

$750K in 4 rounds

Latest Funding Round

Post IPO, Dec 10, 2024, $*****

Investors

East West Capital Partners

Ranked

1031^st among 3189 active competitors

Annual Revenue

$1M as on Sep 30, 2025

Employee Count

12 as on Mar 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3030 more

Exit Details

Public

View Sonnet BioTherapeutics' full profile

Sonnet BioTherapeutics is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
SONNET BIOTHERAPEUTICS INC CIN: 473788572 , United States, Active	Dec 31, 1999	-	13 (As on Dec 31, 2024)	-
SONNET BIOTHERAPEUTICS HOLDINGS, INC. CIN: 20-2932652 , United States, Active	Oct 20, 1999	$1M (As on Sep 30, 2025)	12 (As on Sep 30, 2023)	-

Sonnet BioTherapeutics got listed on Apr 02, 2020.

Click here to take a look at Sonnet BioTherapeutics's IPO in detail

Sonnet BioTherapeutics has raised a total funding of $750K over 4 rounds. Its first funding round was on May 14, 2019. Sonnet BioTherapeutics has 1 institutional investor.

Here is the list of recent funding rounds of Sonnet BioTherapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 10, 2024	5301881	Post IPO	5780027	5828163	9207048	1125853
Jul 17, 2023	8279935	Post IPO	8177392	9319108	8700075	6409698
Aug 25, 2020	6223072	Post IPO	9991322	6730332	8100208	9239253

Access funding benchmarks and valuations. Sign up today!

View details of Sonnet BioTherapeutics's funding rounds and investors

The founders of Sonnet BioTherapeutics is Pankaj Mohan. Pankaj Mohan is the CEO of Sonnet BioTherapeutics.

Here are the details of Sonnet BioTherapeutics' key team members:

Pankaj Mohan: Founder & CEO & Chairman  of Sonnet BioTherapeutics.
Contact Info: 1 email address

View details of Sonnet BioTherapeutics's Founder profiles and Board Members

Sonnet BioTherapeutics' employee count trend

Sonnet BioTherapeutics has 12 employees as of Mar 26. Here is Sonnet BioTherapeutics's employee count trend over the years:

Employee count trend for Sonnet BioTherapeutics

Uncover Sonnet BioTherapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Sonnet BioTherapeutics include Jazz Pharmaceuticals, Moderna and Advanced Accelerator Applications. Here is the list of Top 10 competitors of Sonnet BioTherapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Prospect Venture Partners, Versant Ventures ... & 14 others	81/100
2nd	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	HHS, Merck & 30 others	81/100
3rd	Advanced Accelerator Applications 2002, Saint Genis Pouilly (France), Acquired	Novartis company, developing molecular nuclear medicine theranostics	$56.1M	Life Sciences Capital, Vivo Capital & 4 others	77/100
4th	Karyopharm 2008, Natick (United States), Public	Developer of small molecule drugs for the treatment of cancer and inflammatory disease	$98.4M	Foresite Capital, HealthCor Management & 15 others	75/100
5th	Immunocore 2008, Abingdon (United Kingdom), Public	Developer of drugs based on T-Cell receptor technology for the treatment of cancer	$601M	Malin PLC, General Atlantic & 50 others	75/100
6th	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Zhongguancun Development Group ... & 13 others	74/100
7th	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	PMV, VIB & 20 others	74/100
8th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 25 others	74/100
9th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Delos Capital Partners, RusnanoMedInvest ... & 19 others	74/100
10th	Alector 2013, San Francisco (United States), Public	Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders	$215M	AbbVie, The Dementia Discovery Fund & 20 others	74/100
1031st	Sonnet BioTherapeutics 2011, Princeton (United States), Public	Developer of immunotherapies for the treatment of cancer	$750K	East West Capital Partners	57/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Sonnet BioTherapeutics's competitors? Click here to see the top ones

Sonnet BioTherapeutics has made no investments or acquisitions yet.

Here is the latest report on Sonnet BioTherapeutics's geography:

Free

FinTech - US Quarterly Funding Report

Edition: Quarter 1, 2025 (43 Pages)

View all reports related to Sonnet BioTherapeutics

Media has covered Sonnet BioTherapeutics for a total of 28 events in the last 1 year, 8 of them have been about company updates and 2 about people movement.